D Pongratz

Ludwig-Maximilians-University of Munich, München, Bavaria, Germany

Are you D Pongratz?

Claim your profile

Publications (175)324.3 Total impact

  • Source

  • Source

  • Source

  • [Show abstract] [Hide abstract]
    ABSTRACT: The need for clinical awareness and diagnostic precision of glycogen storage disease type 2 (GSD2) has increased, as enzyme replacement therapy has become available. So far, only small series have reported the muscle pathology of late-onset GSD2. We reassessed 43 muscle biopsies of 38 GSD2 patients. In all patients the diagnosis of GSD2 has been established by biochemistry and/or mutational analysis of the GAA gene. Additionally to the expected morphological features, ultrastructural analysis revealed a high incidence of autophagic vacuoles, lipofuscin debris, structural Z-line disorganization and histological neurogenic-like pattern that were not thoroughly appreciated, previously. Comparing age at onset and morphology, excessive vacuolar and autophagic myopathy and mitochondrial disorganization of virtually all fibres is common in infants. At juvenile onset, a more moderate vacuolization without significant differences in overall morphology is notable. At late-onset, the spectrum of vacuolar myopathy is more divergent, ranging from almost normal to severe. Here pronounced secondary alterations are observed that include lipofuscin debris, autophagic vacuoles with residual lysosomal bodies and granular inclusions, structural mitochondrial and Z-line texture alterations. Moreover, there is a high incidence of subtle neurogenic-like alteration in all subtypes. Nineteen patients were genetically tested; in 15 patients the common leaky splicing mutation c.-45T>G (or IVS1-13T>G) in intron1 of the GAA gene was found on at least one allele, facilitating genetic screening. In our patients, GAA genotype appears not to be associated with secondary alterations such as autophagic vacuoles, structural alterations or neurogenic-like changes. These findings may have implications for our understanding of the pathogenesis of GSD2 and for assessing therapeutic success of enzyme replacement therapy.
    Neuropathology and Applied Neurobiology 11/2007; 33(5):544-59. DOI:10.1111/j.1365-2990.2007.00839.x · 3.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We report on two unrelated patients clinically presenting with late-onset progressive limb girdle weakness; cardiomyopathy was seen in one patient. Muscle biopsy revealed a necrotic myopathy with numerous rimmed vacuoles, ultrastructurally typical paired-helical filaments, and reduced immunohistochemical staining for alpha-dystroglycan. Quadriceps sparing hereditary inclusion body myopathy due to mutations in GNE gene, and OPMD due to PABPN1 mutations were excluded, genetically. We detected a homozygous mutation of the FKRP gene (826C>A) in both patients. Mutations of FKRP have been reported in congenital muscular dystrophies, LGMD2I, cardiomyopathy and hyperCKemia, but not in myopathies with vacuoles and paired-helical filaments. Therefore, our findings further extend the morphological variability of muscular dystrophies due to FKRP mutations.
    Acta myologica: myopathies and cardiomyopathies: official journal of the Mediterranean Society of Myology / edited by the Gaetano Conte Academy for the study of striated muscle diseases 10/2006; 25(2):73-6.
  • Source
    Dieter Pongratz ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Polymyositis, dermatomyositis, and inclusion body myositis are idiopathic inflammatory myopathies of unknown etiology with autoimmune pathogenesis. For choosing an individual and efficient therapy, diagnostic assignment is an important factor. Therapeutic options in dermatomyositis and polymyositis include corticosteroids and immunosuppressives. Intravenous immunoglobulins are only needed in special cases. In inclusion body myositis, corticosteroids and immunosuppressives are not successful. At the moment intravenous immunoglobulins are the only therapeutic possibility.
    Journal of Neurology 10/2006; 253 Suppl 5(S5):V64-5. DOI:10.1007/s00415-006-5010-2 · 3.38 Impact Factor
  • D Pongratz ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Immunogenic inflammatory myopathies are a heterogeneous group of acquired muscle disorders. Clinical and morphological characteristics are on one side muscle weakness, on the other side inflammatory infiltrates in muscle biopsy. Three main groups of different pathogenesis and course can be subdivided: The treatment of inflammatory myopathies is predominantly based on empiric data. Baseline drugs are Corticosteroids and Immunosuppressives. High dose intravenous Immunoglobulins (IVIG) are an important additional therapeutic possibility, especially in inclusion body myositis.
    DMW - Deutsche Medizinische Wochenschrift 03/2006; 131(7):330-6; quiz 337-8. · 0.54 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The distinction between multifocal motor neuropathy, treatable by intravenous immunoglobulins (IVIg), and degenerative motor neurone disorders is often difficult. To find predictive factors for the response to IVIg treatment, 40 consecutive patients with pure lower motor neurone disorders (LMND) were prospectively examined. They all received at least two times IVIg (2 g/kg bodyweight). Prior to the first and before all the following treatments a standardized evaluation was performed including clinical examination, neurophysiological and laboratory evaluation. According to changes in the neurological examination and the Neuromuscular Symptom Score, the patients were divided into responders and non-responders after the second course of treatment. In our study, no single clinical, neurophysiological, or laboratory parameter was sensitive enough to predict response. The only single parameter that highly correlated with a positive response to treatment was an elevated GM1 antibody titre. Lack of response to IVIg treatment is likely in patients with generalization of electromyographic signs of denervation beyond the clinically involved site, proximal localization of the weakness, and an elevated level of the creatinekinase. Conduction blocks do not distinguish between both groups. We propose a scoring system combining clinical, serological and neurophysiological data in order to decide which patients with LMND may receive IVIg.
    European Journal of Neurology 03/2006; 13(2):135-40. DOI:10.1111/j.1468-1331.2006.01142.x · 4.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We monitored serum levels of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) before and during intravenously applied immunoglobulin (IVIG) therapy in 33 patients with chronic immune-mediated neuropathies and myopathies and 15 controls. Baseline MMP-2 and TIMP-2 serum levels were lower and MMP-9 and TIMP-1 serum levels higher in all patients compared to age-matched controls. Eight days after IVIG treatment, MMP-2, TIMP-2, and TIMP-1 serum levels increased, while MMP-9 serum levels decreased, indicating tissue repair. After 60 days, MMP-9 levels increased, MMP-2 approached normal levels, while TIMP-1 and TIMP-2 serum levels were below day 8 levels, indicating relapsing tissue damage. Comparing the MMP/TIMP results with the clinical courses, IVIG treatment tended to change MMP/TIMP levels in a way that paralleled clinical improvement and relapse. In sum, during a distinct time period, IVIG therapy seems to be able to modulate MMP-mediated tissue repair.
    European Neurology 02/2006; 55(4):204-8. DOI:10.1159/000093870 · 1.36 Impact Factor
  • B G H Schoser · D Pongratz ·
    [Show abstract] [Hide abstract]
    ABSTRACT: A growing number of therapeutic agents and exogenous toxins are harmful to structure and function of human skeletal muscle. The clinical syndrome encompasses asymptomatic creatine kinase elevation, myalgia, exercise intolerance, muscle paresis and atrophy, and lastly acute rhabdomyolysis. Toxic myopathies are potentially reversible, hence a prompt recognition is particularly helpful for the early diagnosis and in conclusion elimination of a myopathy inducing toxin. Toxic myopathies may be classified as acute or chronic accordingly to the exposition time to a toxin. Main source of an exogenous induced toxic myopathy is chronic alcohol abuse. Alcohol excess induces acute and/or chronic neuropathy and myopathy, consequently muscle wasting and weakness occurs. Drug-induced myopathies are most frequently seen due to amplified utilization of corticosteroids or lipid lowering agents.
    Der Internist 12/2005; 46(11):1198-206. · 0.31 Impact Factor
  • B. G. H. Schoser · D. Pongratz ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Eine zunehmende Anzahl von therapeutisch eingesetzten Substanzen und exogenen Toxinen führt zu strukturellen und funktionellen Veränderungen der Skelettmuskulatur. Das klinische Syndrom toxischer Myopathien variiert von symptomfreier Kreatinkinaseerhöhung über Muskelschmerzen mit Belastungsinsuffizienz, Schwäche und Atrophie bis hin zur akuten Rhabdomyolyse. Aufgrund der potenziellen Reversibilität einer toxischen Myopathie sollte der kausale Zusammenhang möglichst rasch erkannt werden und dann die Diagnosestellung und Elimination der Noxe erfolgen. Häufigste Ursache einer exogenen toxischen Myopathie ist die Alkoholkrankheit, die sowohl zu akuten als auch chronischen Neuropathien und Myopathien mit konsekutiver Muskelatrophie führt. Unter den medikamentös induzierten Myopathien hat neben der steroidinduzierten Myopathie zurzeit die durch Lipidsenker ausgelöste Myopathie die höchste Relevanz.
    Der Internist 11/2005; 46(11):1198-1206. DOI:10.1007/s00108-005-1490-x · 0.31 Impact Factor
  • A Haberl · P Fischer · D Pongratz · J P Sieb ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The myotoxicity of chloroquine and hydroxychloroquine has been known for decades. Limb-girdle weakness due to a vacuolar myopathy may occur occasionally in a dose-dependent manner during the first 24 months on chloroquine. However, we report on a case in which muscular weakness developed after a daily intake of 250 chloroquine phosphate (= 155 mg chloroquine base) for a period of 7 years. Even after long-term and apparently well-tolerated chloroquine treatment, the occurrence of severe side-effects is possible.
    Zeitschrift für Rheumatologie 06/2005; 64(4):274-6. · 0.61 Impact Factor
  • A. Haberl · P. Fischer · D. Pongratz · J. P. Sieb ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Die Myotoxizitt von Chloroquin und Hydroxychloroquin ist langjhrig bekannt. blicherweise kann es dosisabhngig in den ersten 24 Monaten der Medikation zur Entwicklung einer Gliedergrtelschwche im Rahmen einer vakuolren Myopathie kommen. Wir berichten ber einen Fall mit Ausbildung einer Muskelschwche nach siebenjhriger Einnahme von tglich 250 mg Chloroquinphosphat (=155 mg Chloroquinbase). Auch nach langjhriger, scheinbar gut vertragener Chloroquinmedikation muss auf die Ausbildung relevanter Nebenwirkungen geachtet werden.The myotoxicity of chloroquine and hydroxychloroquine has been known for decades. Limb-girdle weakness due to a vacuolar myopathy may occur occasionally in a dose-dependent manner during the first 24 months on chloroquine. However, we report on a case in which muscular weakness developed after a daily intake of 250 chloroquine phosphate (= 155 mg chloroquine base) for a period of 7 years. Even after long-term and apparently well-tolerated chloroquine treatment, the occurrence of severe side-effects is possible.
    Zeitschrift für Rheumatologie 04/2005; 64(4):274-276. DOI:10.1007/s00393-005-0576-0 · 0.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Deficiencies of different proteins involved in copper metabolism have been reported to cause human diseases. Well-known syndromes, for example, are Menkes and Wilson diseases. Here we report a patient presenting with congenital cataract, severe muscular hypotonia, developmental delay, sensorineural hearing loss and cytochrome-c oxidase deficiency with repeatedly low copper and ceruloplasmin levels. These findings were suggestive of a copper metabolism disorder. In support of this, the patient's fibroblasts showed an increased copper uptake with normal retention. Detailed follow-up examinations were performed. Immunoblotting for several proteins including ATP7A (MNK or Menkes protein), ATP7B (Wilson protein) and SOD1 showed normal results, implying a copper metabolism defect other than Wilson or Menkes disease. Sequence analysis of ATOX1 and genes coding for proteins that are known to play a role in the mitochondrial copper metabolism (COI-III, SCO1, SCO2, COX11, COX17, COX19) revealed no mutations. Additional disease genes that have been associated with cytochrome-c oxidase deficiency were negative for mutations as well. As beneficial effects of copper histidinate supplementation have been reported in selected disorders of copper metabolism presenting with low serum copper and ceruloplasmin levels, we initiated a copper histidinate supplementation. Remarkable improvement of clinical symptoms was observed, with complete restoration of cytochrome-c oxidase activity in skeletal muscle.
    Journal of Inherited Metabolic Disease 02/2005; 28(4):479-92. DOI:10.1007/s10545-005-0479-x · 3.37 Impact Factor
  • Source

    Journal of Medical Genetics 12/2004; 41(11):842-8. DOI:10.1136/jmg.2004.020271 · 6.34 Impact Factor
  • D Pongratz ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Polymyalgia rheumatica occurs mainly in patients older than 60 years of age. Differential diagnostically, the condition can be identified on the basis of a number of laboratory parameters (ESR, CRP, CK, autoantibodies) and, if the findings are not unequivocal, the additional use of electromyography and muscle biopsy. Some 40-50% of the patients have concomitant giant cell arteritis. Treatment of polymyalgia rheumatica is glucocorticoids are applied, usually for a period of at least one year. The initial and the tapered dose is dependent on whether an associated arteritis is present.
    MMW Fortschritte der Medizin 12/2004; 146(46):32-4.
  • Source

    Journal of Medical Genetics 07/2004; 41(6):e75. DOI:10.1136/jmg.2003.015024 · 6.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Several forms of recessive limb girdle muscular dystrophy (LGMD2C-F) are due to mutations in genes coding for sarcoglycans. Clinically, most sarcoglycanopathies present in childhood with skeletal muscle wasting and early loss of ambulation; respiratory insufficiency is rare. However, some cases of LGMD2D with a late onset and a milder course have been reported. In this study, two adult brothers, compound heterozygous for two missense mutations of the SGCA gene (Arg77Cys, Val247Met), presented with respiratory insufficiency while they were still ambulatory.
    Acta myologica: myopathies and cardiomyopathies: official journal of the Mediterranean Society of Myology / edited by the Gaetano Conte Academy for the study of striated muscle diseases 06/2004; 23(1):1-5.
  • Source

    Journal of Medical Genetics 05/2004; 41(4):e50. · 6.34 Impact Factor
  • M Späth · T Stratz · G Neeck · I Kötter · B Hammel · C C Amberger · U Haus · L Färber · D Pongratz · W Müller ·
    [Show abstract] [Hide abstract]
    ABSTRACT: To determine the efficacy of a serotonin receptor (5-HT(3)) antagonist in the treatment of fibromyalgia (FM) in a prospective, randomized, double-blind, placebo-controlled, multicentre trial. Twenty-one female patients (age 21-63 years) with FM according to the American College of Rheumatology classification criteria for FM were assigned randomly to either a placebo group or to receive a daily intravenous bolus injection of 5 mg tropisetron for 5 days. In patients receiving tropisetron, the visual analogue scale (VAS) score for pain decreased by 28.9 compared with a decrease of 6.8 in the placebo group [probability (p)=0.063; effect size: 0.794]. Similar results were obtained using a body diagram pain score as a secondary efficacy parameter: mean pain reduction was 27.2 in the tropisetron group, versus 2.8 in the placebo group (p=0.038; effect size: 0.902). 5-HT(3) receptor antagonists provide significant pain relief for a group of FM patients.
    Scandinavian Journal of Rheumatology 02/2004; 33(4):267-70. DOI:10.1080/03009740410005818 · 2.53 Impact Factor

Publication Stats

2k Citations
324.30 Total Impact Points


  • 1993-2007
    • Ludwig-Maximilians-University of Munich
      • • Department of Neurology
      • • Friedrich-Baur-Institute
      München, Bavaria, Germany
  • 2004
    • Technische Universität Dresden
      • Department of Neuroradiology
      Dresden, Saxony, Germany
  • 1999-2004
    • Friedrich Loeffler Institute
      Griefswald, Mecklenburg-Vorpommern, Germany
  • 2000
    • Universität Regensburg
      • Institute of Pharmacy
      Ratisbon, Bavaria, Germany
  • 1996
    • Technische Universität München
      München, Bavaria, Germany
  • 1995
    • Max Planck Institute of Biochemistry
      München, Bavaria, Germany
  • 1975-1992
    • University Hospital München
      München, Bavaria, Germany
  • 1973-1976
    • Deutsches Herzzentrum München
      München, Bavaria, Germany